Bicarbonate

Bicarbonate

SCHEMBL5359209

O=C([O-])[O-].O=C([O-])[O-].[Ca+2].[Fe+2]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.46
CA1 P00915 3/20 0.46
FAHD1 Q6P587 1/20 0.46
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
LDHA P00338 1/20 0.36
BLM P54132 1/20 0.36
KMT2A Q03164 1/20 0.36
CASP1 P29466 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL8674948 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL6562090 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL16098384 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL10821897 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL4958654 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL5491026 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL9247439 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL7608551 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL1701669 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9
Bicarbonate SCHEMBL4338785 0.94 CA1 (0.56) CA4CA1FAHD1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119240711-A Improved pretreatment method for silicon-implanted body in laboratory 青岛海洋科技中心 2025-01-03 CN claimed
CN-118892468-A Roxithromycin capsule and preparation method thereof 南京恒远科技开发有限公司 2024-11-05 CN claimed
CN-221288240-U Heavy calcium carbonate deironing device 河南美得装饰材料有限公司 2024-07-09 CN claimed
CN-111419820-B Desloratadine citrate disodium capsule and preparation method and application thereof 合肥医工医药股份有限公司 2022-03-25 CN claimed
CN-111419820-A Desloratadine citrate disodium capsule and preparation method and application thereof 合肥医工医药股份有限公司 2020-07-17 CN claimed
CN-101198558-B Natural marble like crystallized glass and process for production thereof NIPPON ELECTRIC GLASS CO 2013-05-08 CN claimed
US-7111847-B2 Self-dispensing bullet trap buffer block THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2006-09-26 US claimed
EP-1092690-B1 Method of producing a cement with reduced content of chromium POVAZSKA CEMENTAREN AS (SK) 2005-07-13 EP claimed
US-20050006849-A1 Self-dispensing bullet trap buffer block US GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY 2005-01-13 US claimed
EP-1412284-A2 COMPOSITION FOR TREATING CELLS AND METHODS FOR QUALITATIVELY AND QUANTITATIVELY CUSTOMIZING THE FORMULATION THEREOF FOR A HEURISTICALLY DERIVED LIVING CELL NUTRIENT-COMPOSITION-ON-DEMAND Runkis, Walter H. (US) 2004-04-28 EP claimed
US-20030073580-A1 Composition for treating cells and method for qualitatively and quantitatively customizing the formulation thereof RUNKIS WALTER H (US) 2003-04-17 US claimed
WO-2002100772-A2 COMPOSITION AND METHOD FOR TREATING CELLS AND PLANTS RUNKIS WALTER H (US) 2002-12-19 WO claimed
EP-1092690-A1 Method of producing a cement with reduced content of chromium Povazská cementáren, a.s. (SK) 2001-04-18 EP claimed
CN-122035916-A Whitening method for preparing precipitated calcium carbonate from high-content iron ore 晓光新材料科技(湘西)有限公司 2026-05-15 CN disclosed
US-20260003096-A1 DETERMINATION OF MINERALOGY AND LITHOLOGY FROM ELEMENTAL DATA HALLIBURTON ENERGY SERVICES, INC. (US) 2026-01-01 US disclosed
CN-119240711-A Improved pretreatment method for silicon-implanted body in laboratory 青岛海洋科技中心 2025-01-03 CN disclosed
EP-1412284-A2 COMPOSITION FOR TREATING CELLS AND METHODS FOR QUALITATIVELY AND QUANTITATIVELY CUSTOMIZING THE FORMULATION THEREOF FOR A HEURISTICALLY DERIVED LIVING CELL NUTRIENT-COMPOSITION-ON-DEMAND Runkis, Walter H. (US) 2004-04-28 EP disclosed
US-20030073580-A1 Composition for treating cells and method for qualitatively and quantitatively customizing the formulation thereof RUNKIS WALTER H (US) 2003-04-17 US disclosed
WO-2002100772-A2 COMPOSITION AND METHOD FOR TREATING CELLS AND PLANTS RUNKIS WALTER H (US) 2002-12-19 WO disclosed
EP-1092690-A1 Method of producing a cement with reduced content of chromium Povazská cementáren, a.s. (SK) 2001-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260003096-A1 DETERMINATION OF MINERALOGY AND LITHOLOGY FROM ELEMENTAL DATA DEGS1, CACNG7, LBR CA4 1518/4885CA1 126/4885FAHD1 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.